SMYD2 and cancer: As shown in Figure 4B, the number of viable cells was significantly decreased with the inhibitor treatment in a dose-dependent manner, implying that an inhibitor(s) targeting SMYD2 could suppress SMYD2-mediated β-catenin methylation, reduce β-catenin nuclear translocation, and subsequently induce cancer cell death.